ライフサイエンスコーパス: end-stage

1 es of disease (between 40 and 60 days) until end-stage.

2 , was shown to be at reduced levels in human end-stage cardiomyopathy, thus making Mgat1 an attractiv

3 GT is life-saving for patients with end-stage CIPO and HPN-associated complications.

4 complicated by their failure to develop the end-stage complications which characterize the human phe

5 Ten inactive fibrotic nodules, identical to end-stage de novo lesions, were found and were presumed

6 Further, early and late end stage disease, while largely similar, had several di

7 ingly used to rescue patients with CIPO with end-stage disease and home parenteral nutrition (HPN)-as

8 mained the optimal therapy for patients with end-stage disease, extending and improving quality of li

9 and the accrual of proteinaceous deposits at end-stage disease.

10 gan transplantation as an option to overcome end-stage diseases is common in countries with advanced

11 End-stage dSod1 (G85R) animals of both sexes exhibit sev

12 End-stage (ES) hypertrophic cardiomyopathy (HCM) has bee

13 llowed by sequencing in 70 human control and end-stage failing hearts.

14 The term "end stage" has been used to describe hypertrophic cardio

15 etal reprogramming upon stress culminates in end-stage heart failure (HF) by mechanisms that are not

16 Coronary arteries from patients with end-stage heart failure caused by ischemic cardiomyopath

17 uals reached the primary end point (52 [68%] end-stage heart failure events, 24 [32%] malignant ventr

18 -evaluate clinical profile and prognosis for end-stage heart failure in a large HCM cohort with conte

19 With the growing volume of end-stage heart failure patients receiving VADs, an incr

20 d emergent abdominal operations performed in end-stage heart failure patients supported with ventricu

21 rt- and long-term survival for patients with end-stage heart failure, and the majority of these recip

22 is increased in ventricles of patients with end-stage heart failure, increased basal open probabilit

23 VAD), a mainstay of therapy for advanced and end-stage heart failure, remain plagued by device thromb

24 rtant proportion of qualifying patients with end-stage heart failure.

25 ife and survival for patients suffering from end-stage heart failure.

26 AD) therapy has become an important tool for end-stage heart failure.

27 been accepted as the standard treatment for end-stage heart failure.

28 ct group of muscular dystrophy patients with end-stage heart failure.

29 site of malignant ventricular arrhythmia and end-stage heart failure.

30 MyoFb in end-stage HF have a variable degree of differentiation a

31 an ventricular myocardium from patients with end-stage HF, we found high levels of phosphorylated his

32 in a risk model of survival termed Model for End-Stage Intestinal Failure (MESIF) (C-statistic 0.78).

33 the heart was significantly reduced in human end-stage ischemic cardiomyopathy in comparison to nonfa

34 f these RNases were evident in patients with end stage kidney disease prior to PD initiation, and ome

35 ality and technique failure in patients with end stage kidney failure who receive peritoneal dialysis

36 SGLT2 inhibitors also reduced end-stage kidney disease (0.65, 0.53-0.81, p<0.0001), an

37 igher as compared with ICU control group non-end-stage kidney disease (25% vs 41.4%; p = 0.005).

38 The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or

39 erum creatinine (sustained for >=30 days) or end-stage kidney disease (eGFR <15 mL/min per 1.73 m(2)

40 the other hand, are at the increased risk of end-stage kidney disease (ESKD) after donation compared

41 er, long-term outcomes such as mortality and end-stage kidney disease (ESKD) have been rarely reporte

42 sociation with CKD risk factors and incident end-stage kidney disease (ESKD) in 4,843 participants of

43 ranging from stage 1 to stage 5 CKD, whereas end-stage kidney disease (ESKD) is defined as permanent

44 End-stage kidney disease (ESKD) patients are living long

45 to decline in glomerular filtration rate and end-stage kidney disease (ESKD), has been replaced by a

46 sistently associated with subsequent risk of end-stage kidney disease across a range of cohorts, lend

47 imary outcome of interest was development of end-stage kidney disease after a baseline period of 2 ye

48 ing problem across the world and can lead to end-stage kidney disease and cardiovascular disease.

49 End-stage kidney disease and dialysis vintage are charac

50 lication of type 2 diabetes that can lead to end-stage kidney disease and is associated with high car

51 versies Conference on CAD and CKD (including end-stage kidney disease and transplant recipients) seek

52 the optimal treatment for most patients with end-stage kidney disease but organ shortage is a major c

53 lamines that precede the clinical outcome of end-stage kidney disease by several years.

54 lar morbidity and mortality in patients with end-stage kidney disease could be partially caused by ex

55 Data for 675 904 individuals and 7461 end-stage kidney disease events were available for our p

56 the past 2 decades, while incident rates of end-stage kidney disease have climbed.

57 nsplant waitlisting within the first year of end-stage kidney disease have remained unchanged over th

58 on between change in albuminuria and risk of end-stage kidney disease in a large individual participa

59 leading cause of chronic kidney disease and end-stage kidney disease in children.

60 e in albuminuria as a surrogate endpoint for end-stage kidney disease in clinical trials of progressi

61 CKD and end-stage kidney disease not only increase the risk of C

62 We excluded patients who had end-stage kidney disease or AKI at admission.

63 ed period of 8 months to 4 years, subsequent end-stage kidney disease or mortality follow-up data, an

64 Data about end-stage kidney disease patients admitted to the ICU ar

65 and to determine the prognostic factors for end-stage kidney disease patients admitted to the ICU.

66 n among 34 857 incident, adult (18-79 years) end-stage kidney disease patients from 690 dialysis faci

67 End-stage kidney disease patients presented frequently s

68 aortic valve calcification in patients with end-stage kidney disease receiving hemodialysis in addit

69 to standard therapy, in adult patients with end-stage kidney disease receiving hemodialysis.

70 he past few decades, rates of progression to end-stage kidney disease remain high with no beneficial

71 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio,

72 tive risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine l

73 ion or died of kidney disease, 335 developed end-stage kidney disease, and 943 had acute kidney injur

74 diagnosis, 5-20% of patients with LN develop end-stage kidney disease, and the multiple comorbidities

75 han 1% absolute reduction in 10-year risk of end-stage kidney disease, even at early stages of chroni

76 [or increase in creatinine], progression to end-stage kidney disease, or death attributable to kidne

77 th nephrotic syndrome that often progress to end-stage kidney disease.

78 disease and one of the most common causes of end-stage kidney disease.

79 antation (KT) is the treatment of choice for end-stage kidney disease.

80 sistently associated with subsequent risk of end-stage kidney disease.

81 h type 2 diabetes at high risk of developing end-stage kidney disease.

82 iovascular adverse events and progression to end-stage kidney disease.

83 eterogeneity and exponential accumulation of end-stage kidney diseases over time prevent long-term pr

84 dney function, but many patients progress to end-stage kidney failure despite optimal therapy.

85 ey glomerulosclerosis commonly progresses to end-stage kidney failure, but pathogenic mechanisms are

86 dependent risk factor for the progression to end-stage kidney failure, cardiovascular morbidity, and

87 Diabetic nephropathy is a leading cause of end-stage kidney failure.

88 A pediatric end -stage liver disease score >=40, postoperative hospi

89 f cirrhosis and hepatic failure resulting in end stage liver disease with limited pharmacological opt

90 L) mortality is adjudicated by the Model for End Stage Liver Disease-Sodium (MELD-Na) score.

91 f patients with cirrhosis have low Model for End Stage Liver Disease-Sodium (MELD-Na) scores, however

92 the discriminative ability of LFI+Model for End Stage Liver Disease-sodium (MELDNa) versus MELDNa al

93 DS, non-AIDS cancer, cardiovascular disease, end-stage liver and renal disease, death) was compared b

94 Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease >15 before being offered to loca

95 Among HIV-infected, model of end-stage liver disease (aHR, 1.04; P < 0.001), body mas

96 Sixty-eight participants with end-stage liver disease (Child-Turcotte-Pugh score >=7 a

97 identify a prognostic profile that predicts end-stage liver disease (ESLD) events including ascites,

98 End-stage liver disease (ESLD) is a major burden on publ

99 Patients with end-stage liver disease (ESLD) suffer from a high sympto

100 mpare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular

101 al Condition Category 83), 2.55 (2.35-2.77); end-stage liver disease (Hierarchical Condition Category

102 s were diabetes, chronic kidney disease, and end-stage liver disease (HR = 1.2, 95% CI = 1.0-1.4 when

103 a parsimonious model consisting of Model for End-Stage Liver Disease (MELD) and LA at admission may p

104 ients' disease severity, using the Model for End-Stage Liver Disease (MELD) in 8387 French patients w

105 The Model for End-Stage Liver Disease (MELD) is used for clinical deci

106 isted for SLKT, stratified by base Model for End-Stage Liver Disease (MELD) score (<=20, 21-30, >30).

107 95) and performed well compared to Model for End-Stage Liver Disease (MELD) score (C-statistic, 0.72;

108 too sick." Our primary outcome was Model for End-Stage Liver Disease (MELD) score at waitlist removal

109 n nine adults with cirrhosis and a Model for End-Stage Liver Disease (MELD) score of 10-16 (ISRCTN 10

110 re high-acuity with median biologic model of end-stage liver disease (MELD) score of, 35 for dCLKT an

111 mortality or removal according to model for end-stage liver disease (MELD) score vs ACLF category.

112 as 3.8% (1.5, 6.9), and the median Model for End-Stage Liver Disease (MELD) score was 11.6 (9.4, 14.0

113 ir age, body mass index, diabetes, model for end-stage liver disease (MELD) score, and need for dialy

114 Model for End-Stage Liver Disease (MELD) score-based liver transpl

115 ver disease patients regardless of Model for End-stage Liver Disease (MELD) score.

116 R patients were younger; had lower Model for End-stage Liver Disease (MELD) scores, AFP levels, and n

117 after stratifying patients by the Model for End-Stage Liver Disease (MELD) with a cutoff at 15 (<15

118 Penn to the Mayo Risk Score (MRS), Model for End-Stage Liver Disease (MELD), Model for End-Stage Live

119 ceptance did not vary by candidate model for end-stage liver disease (MELD), the short-term risk peri

120 On multivariate analysis, high Model for End-Stage Liver Disease (MELD; odds ratio [OR], 1.10; co

121 npatients, 63% were male patients, model for end-stage liver disease (MELDNa) was 32, and follow up w

122 The current pediatric end-stage liver disease (PELD) score underestimates pedi

123 nd Edinburgh with a United Kingdom Model for End-Stage Liver Disease (UKELD) score >=62 were register

124 to be first-time recipients with a model for end-stage liver disease 15-34, without primary biliary c

125 ed by joint-effect model (based on Model for End-Stage Liver Disease [MELD] and Lille scores).

126 e, 50.4 +/- 11.8 years; 84% males; Model for End-Stage Liver Disease [MELD], 19.9 +/- 9.9), 36% had A

127 obiome alterations correlated with model for end-stage liver disease and Child-Pugh scores and organ

128 alysis of covariance, adjusted for model for end-stage liver disease at time of hospital admission, s

129 pediatric end-stage liver disease/model for end-stage liver disease at transplant for infants (29 ve

130 ients and even more frequently in those with end-stage liver disease because of inadequate adherence

131 olangiopathy that progresses to fibrosis and end-stage liver disease by 2 years of age.

132 However, end-stage liver disease caused by chronic Cryptosporidiu

133 f acute kidney injury (AKI) in patients with end-stage liver disease constitutes one of the most chal

134 Despite uniform HCC Model for End-Stage Liver Disease exception across height and sex,

135 ld be given to awarding additional Model for End-Stage Liver Disease exception points to these patien

136 s measured primarily by the use of model for end-stage liver disease excluding international normaliz

137 We evaluated 86 patients with end-stage liver disease for variants in an expanded pane

138 t was only significant in the high Model for End-Stage Liver Disease group (P < 0.001).

139 nt of preventive measures and treatments for end-stage liver disease in elderly patients.

140 Despite the increasing prevalence of end-stage liver disease in older adults, there is no con

141 CCM) is cardiac dysfunction in patients with end-stage liver disease in the absence of prior heart di

142 The complexity of end-stage liver disease may warrant more intensive care

143 p = 0.001) or after adjusting for Model for End-stage Liver Disease or Sequential Organ Failure Asse

144 Despite HCV cure, 12 end-stage liver disease participants required subsequent

145 ed patients develop fibrosis and progress to end-stage liver disease requiring liver transplantation

146 impairment (Child-Pugh class C or model for end-stage liver disease score >=19) were eligible.

147 R, 0.29; 95% CI, 0.03-0.99), and a model for end-stage liver disease score >=25 (HR, 0.26; 95% CI, 0.

148 tion, or ablation and a calculated model for end-stage liver disease score <15 at HCC diagnosis.

149 (Child-Turcotte-Pugh score >=7 and Model for End-Stage Liver Disease score 6-29) were enrolled, 26 ha

150 e 88 patients transplanted, median model for end-stage liver disease score at LT was 7 ((interquartil

151 gorized into three groups based on Model for End-Stage Liver Disease score at transplant: lower-score

152 Model for End-Stage Liver Disease score pretransplantation and the

153 The Model for End-Stage Liver Disease score was lower in the DCD SLK g

154 The median model for end-stage liver disease score was similar between the ge

155 (mean age, 56 years; 61% men; mean model for end-stage liver disease score, 19.5).

156 rity, indicated by a higher median Model for End-Stage Liver Disease score, and associated with incre

157 model based on comorbidity burden, Model for End-Stage Liver Disease score, and serum level of albumi

158 ) recipients, the weighting of the model for end-stage liver disease score, and the increased prevale

159 ts in both groups had similar age, model for end-stage liver disease score.

160 of 28-day mortality together with Model for End-Stage Liver Disease score.

161 e North American Consortium for the Study of End-Stage Liver Disease sites from 2015 through 2017 (me

162 ed: age, female sex, lactate value, Model of End-Stage Liver Disease XI score, history of atrial fibr

163 hosis with recurrent HE with MELD (Model for End-Stage Liver Disease) <17 on SOC were randomized 1:1

164 IDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease out

165 IDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease out

166 IDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease.

167 fter matching both groups for age, model for end-stage liver disease, and GRWR.

168 irus (HBV) infections can lead to cirrhosis, end-stage liver disease, and hepatocellular carcinoma.

169 , age of the recipient, laboratory model for end-stage liver disease, donor risk index, period of tra

170 Their median model of end-stage liver disease, incorporating serum sodium scor

171 des (P = 0.02); independent of age, model of end-stage liver disease, incorporating serum sodium scor

172 IDS-defining cancers, myocardial infarction, end-stage liver disease, or end-stage renal disease outc

173 n with 4 DSA factors: median match model for end-stage liver disease, proportion of white deaths out

174 In patients with end-stage liver disease, the ability to predict recovery

175 s well-recognized phenomena in patients with end-stage liver disease, the impact of gut dysbiosis and

176 which may not be reflected by the Model for End-Stage Liver Disease-Sodium (MELD-Na) score.

177 f patients with cirrhosis have low Model for End-Stage Liver Disease-Sodium (MELD-Na) scores; however

178 or End-Stage Liver Disease (MELD), Model for End-Stage Liver Disease-Sodium MELD-Na, and Child-Turcot

179 it is not clear which of these low Model for End-Stage Liver Disease-Sodium score patients would bene

180 ed significant after adjusting for model for end-stage liver disease-sodium score, mechanical ventila

181 However, patients with low Model for End-Stage Liver Disease-Sodium scores still suffer from

182 ain asymptomatic until onset of cirrhosis or end-stage liver disease.

183 for liver transplantation even if they have end-stage liver disease.

184 ents such as LTx-recipients or patients with end-stage liver disease.

185 t also medium-term survival of patients with end-stage liver disease.

186 elomere attrition is a major risk factor for end-stage liver disease.

187 uce its diagnostic accuracy in patients with end-stage liver disease.

188 allocation led to decreased median pediatric end-stage liver disease/model for end-stage liver diseas

189 ational children with status 1B or Model for End-Stage Liver Disease/Pediatric End-Stage Liver Diseas

190 cirrhosis different from other etiologies of end-stage liver disease?

191 se of chronic liver disease that can lead to end-stage liver diseases, including cirrhosis and hepato

192 nfarction, stroke, end-stage renal diseases, end-stage liver diseases, or death.

193 In patients with end-stage liver graft disease and CKD, liver retransplan

194 End-stage lung disease and advanced cardiac conditions a

195 Here, we describe 2 patients presenting with end-stage lung disease and significant aortic stenosis w

196 Millions of people worldwide with incurable end-stage lung disease die because of inadequate treatme

197 n is a crucial component in the treatment of end-stage lung disease in infants.

198 lung transplant candidacy for patients with end-stage lung disease in the setting of severe aortic s

199 adult patients may proceed to an early-onset end-stage macular degeneration with frank atrophy of the

200 Though the end-stage neuropathological attributes of AD and primary

201 sis, is not a specific entity but rather the end stage of overlapping disease pathways.

202 features from earlier disease stages to the end stage of RORA could be found, starting with loss of

203 c attack may dominate the process during the end stages of mortality in these conifers.

204 anisms are traditionally associated with the end stages of perception, recent behavioral studies sugg

205 l ganglia pathophysiology is studied only at end-stages of depletion, leaving an impoverished underst

206 Severe fibrosing orchitis (end stage orchitis) was observed at 35 and 70 DPI.

207 plant candidacy of patients with obesity and end-stage organ disease and improve perioperative and po

208 0 deaths in the United States resulting from end-stage organ disease annually.

209 Medical advancements in managing end-stage organ disease have led to an increasing demand

210 ated with obesity, along with the underlying end-stage organ disease leading to transplant candidacy,

211 e treatment of choice for many patients with end-stage organ disease.

212 During end-stage PAH an increase in proteins associated with ap

213 0 +/- 4.93 mmHg) and severe elevation in the end-stage PAH group (50.50 +/- 11.56 mmHg).

214 During end-stage PAH significant changes in RV proteins abundan

215 PLP1 in whom the overall syndrome, including end-stage pathology, indicated a complex disease involvi

216 ilability, or the deterioration and death of end-stage patients before therapy can be implemented.

217 stogram analyses also demonstrated different end-stage patterns between adults and children: Severe h

218 kidney disease (CKD) to predict the risk of end stage renal disease (ESRD), i.e., the need for dialy

219 are living longer, and 11%-18% will develop end stage renal disease (ESRD).

220 Nine patients (42%) had end stage renal disease at a mean age of 10.6 years (6.5

221 gnitive Impairment and Imaging Correlates in End Stage Renal Disease, NCT01883349.

222 option for patients with type 1 diabetes and end stage renal disease.

223 /6J is a protective background and postpones end stage renal failure from 7 weeks, as seen on a C3H b

224 [eGFR] to less than 60 mL/min per 1.73m(2), end-stage renal disease (defined as dialysis for at leas

225 from living donors who subsequently develop end-stage renal disease (ESRD) also have higher graft fa

226 s an independent predictor of posttransplant end-stage renal disease (ESRD) and mortality.

227 neurodegenerative processes in patients with end-stage renal disease (ESRD) compared to healthy contr

228 d 1 in 1,000 people and slowly progresses to end-stage renal disease (ESRD) in about half of these in

229 >=30% decline in eGFR (1.23, 1.15-1.33), and end-stage renal disease (ESRD) or >=50% decline in eGFR

230 se underlying sociocultural factors preclude end-stage renal disease (ESRD) patients from initiating

231 (COPD), asthma, diabetes mellitus (DM), and end-stage renal disease (ESRD) were calculated by Poisso

232 Participants with end-stage renal disease (ESRD) were excluded.

233 Infections are important complications of end-stage renal disease (ESRD) with few studies having i

234 verall, 9%, 5%, and 8% of patients developed end-stage renal disease (ESRD), major cardiovascular eve

235 In patients with end-stage renal disease (ESRD), surgical aortic valve re

236 fibrillation (AF) is common in patients with end-stage renal disease (ESRD).

237 inflamed surface area (PISA) in adults with end-stage renal disease (ESRD).

238 investigate the association between HCM and end-stage renal disease (ESRD).

239 e (odds ratio, 0.18; CI, 0.13-0.25), or with end-stage renal disease (odds ratio, 0.23; CI, 0.13-0.40

240 he best therapeutic option for patients with end-stage renal disease after orthotopic liver transplan

241 vere cardiomyopathy that was associated with end-stage renal disease and characterized by severe func

242 e obese at donation are at increased risk of end-stage renal disease and may benefit from intensive p

243 odies, representing up to 30% of patients in end-stage renal disease and renal transplantation, is th

244 ernative treatment options for patients with end-stage renal disease are being sought.

245 patients undergoing peritoneal dialysis for end-stage renal disease but without cirrhosis were inclu

246 ibute to the inflammatory process underlying end-stage renal disease development in both types of dia

247 d its application for replacement therapy in end-stage renal disease have been widely discussed.

248 al admission, cancer hospital admission, and end-stage renal disease hospital admission) were identif

249 y result in chronic hyperoxaluria, promoting end-stage renal disease in children and young adults.

250 tulated to be involved in the development of end-stage renal disease in diabetes, but which specific

251 ering dialysate temperature in patients with end-stage renal disease is associated with a decrease in

252 Patient survival with end-stage renal disease is longer after kidney transplan

253 Patients with end-stage renal disease on hemodialysis (ESRD-HD) and ao

254 In the human study, participants with end-stage renal disease on peritoneal dialysis (PD) unde

255 Year 5 in NHBs and Year 4 in Hispanics after end-stage renal disease onset.

256 poor with the majority of patients reaching end-stage renal disease or dying with little or no chanc

257 ial infarction, end-stage liver disease, and end-stage renal disease outcomes that could be prevented

258 dial infarction, end-stage liver disease, or end-stage renal disease outcomes.

259 ial infarction, end-stage liver disease, and end-stage renal disease outcomes.

260 monoclonal antibody tesidolumab (LFG316) in end-stage renal disease patients awaiting kidney transpl

261 erapy may be used to treat thyroid cancer in end-stage renal disease patients who undergo hemodialysi

262 ever, limited research has been conducted on end-stage renal disease patients.

263 ette smoking, type II diabetes mellitus, and end-stage renal disease requiring dialysis presented to

264 ette smoking, type II diabetes mellitus, and end-stage renal disease requiring dialysis presented to

265 In up to 15 years, follow-up end-stage renal disease was observed in 1 LD versus 7 TH

266 olled human immunodeficiency virus (HIV) and end-stage renal disease was on the kidney transplant wai

267 ohort design on 29,095 elderly patients with end-stage renal disease who died between 2005 and 2013.

268 e observational ISAR (Risk Stratification in End-Stage Renal Disease) study, data on dynamic retinal

269 (sickle cell nephropathy as primary cause of end-stage renal disease), for a liver transplant 14.3 (r

270 oke, coronary artery disease, heart failure, end-stage renal disease, and dementia.

271 acute kidney injury, chronic kidney disease, end-stage renal disease, and electrolyte abnormalities.

272 panics (versus NHWs) in the first year after end-stage renal disease, but by Year 4, access to transp

273 ath (aORs from 2.4 to 3.8, p <0.05) included end-stage renal disease, coronary artery disease, and ne

274 Prevalence of African American ethnicity, end-stage renal disease, diabetes, fair/poor self-rated

275 All outcome analyses controlled for sex, end-stage renal disease, heart failure, sepsis severity

276 estimated glomerular filtration rate (eGFR), end-stage renal disease, or death from renal causes), th

277 ion is not associated with excess mortality, end-stage renal disease, or morbidity, in at least 10 ye

278 rs reduced heart failure hospitalization and end-stage renal disease.

279 n increase serum hsCRP levels in adults with end-stage renal disease.

280 e and functioning of the kidneys, leading to end-stage renal disease.

281 sease and a requisite for the development of end-stage renal disease.

282 c disorders and the leading genetic cause of end-stage renal disease.

283 ephropathy (DN) remains the leading cause of end-stage renal disease.

284 atient developed a TMA due to CD and reached end-stage renal disease.

285 ial infarction, end-stage liver disease, and end-stage renal disease.

286 erulosclerosis, a condition that can lead to end-stage renal disease.

287 rom ethylene glycol poisoning, can result in end-stage renal disease.

288 disease-related hospitalization or death, or end-stage renal disease.

289 lar lesions, with inescapable progression to end-stage renal disease.

290 ially provider continuity, for patients with end-stage renal disease.

291 f AIDS, acute myocardial infarction, stroke, end-stage renal diseases, end-stage liver diseases, or d

292 th atrial fibrillation include patients with end-stage renal failure (including those receiving dialy

293 ADPKD) is the most common monogenic cause of end-stage renal failure in humans and results from germl

294 ication of diabetes and the leading cause of end-stage renal failure.

295 treatment of hematological malignancies with end-stage renal failure.

296 fections, crescentic glomerulonephritis, and end-stage renal failure.

297 result in impairment in quality of life and end-stage, severe, and/or life-threatening disease.

298 Functional studies at end stage show significantly reduced electrically evoked

299 reduction in angiogenesis that recovered in end-stage tumors.

300 ective loss of excitatory neurons at disease end-stage, which is characterized by prominent nuclear a